DCTH (Delcath Systems) FFO


DCTH Delcath Systems Inc DCTH
70 GF Score
Price $12.23
GF Value $36.69
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Delcath Systems FFO?

FFO (Funds from operations) only applies to REITs.

DCTH
70GF Score
Delcath Systems Inc DCTH
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Delcath Systems (DCTH) Overvalued in 2026?

Based on GuruFocus' analysis, Delcath Systems stock appears to be undervalued. The current stock price of $12.23 is trading 66.7% below its estimated GF Value™ of $36.69. GuruFocus considers Delcath Systems to be Significantly Undervalued.

Key valuation signals for DCTH:

  • FFO:
  • GF Value™: $36.69 vs. price of $12.23 (66.7% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the DCTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Delcath Systems Business Description

Other Exchanges DV3R:Germany
Address 566 Queensbury Avenue, Queensbury, NY, USA, 12804
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
70GF Score

Get the complete analysis for DCTH

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.23
Price
$36.69
GF Value